Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5566453 | 1.00 | LMNA (0.32) | LMNAKDM4E | |
| SCHEMBL5329022 | 0.95 | — | — | |
| SCHEMBL5329015 | 0.95 | — | — | |
| SCHEMBL5327607 | 0.79 | HSD11B1 (0.35) | — | |
| SCHEMBL5329027 | 0.75 | KMT2A (0.37) | LMNAKDM4E | |
| SCHEMBL5566458 | 0.75 | KMT2A (0.39) | LMNAKDM4E | |
| SCHEMBL5332664 | 0.75 | KMT2A (0.37) | LMNAKDM4E | |
| SCHEMBL5566461 | 0.75 | KMT2A (0.39) | LMNAKDM4E | |
| SCHEMBL5329018 | 0.75 | KMT2A (0.37) | LMNAKDM4E | |
| SCHEMBL4977670 | 0.75 | P2RX3 (0.36) | LMNAKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070066674-A1 | Tricyclic imidzopyridines for use as gastric secretion inhibitors | ALTANA PHARMA AG (DE) | 2007-03-22 | — | — | US | disclosed |
| EP-1696921-A1 | TRICYCLIC IMIDAZOPYRIDINES FOR USE AS GASTRIC SECRETION INHIBITORS | Altana Pharma AG (DE) | 2006-09-06 | — | — | EP | disclosed |
| WO-2005058325-A1 | TRICYCLIC IMIDAZOPYRIDINES FOR USE AS GASTRIC SECRETION INHIBITORS | ALTANA PHARMA AG (DE) | 2005-06-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070066674-A1 | Tricyclic imidzopyridines for use as gastric secretion inhibitors | GIPR, SLC10A2, GRPR | LMNA 4864/4885KDM4E 4244/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.